Litsa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-12-2024
- Paid Up Capital ₹ 0.10 M
as on 02-12-2024
- Company Age 10 Year, 30 Days
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2016)
- Profit 183.58%
(FY 2016)
- Ebitda 464.88%
(FY 2016)
- Net Worth 5.44%
(FY 2016)
- Total Assets 663.76%
(FY 2016)
About Litsa Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajiv Kumar and Vandna serve as directors at the Company.
- CIN/LLPIN
U24233UP2014PTC067251
- Company No.
067251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Varanasi, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Litsa Pharmaceuticals Private Limited offer?
Litsa Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Anti Infective Drugs & Medicines, Antiviral Drugs, Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Common Disease Medicines, Antihistamines, Vitamin Tablets & Capsules, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Litsa Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Kumar  | Director | 25-Nov-2014 | Current |
| Vandna | Director | 25-Nov-2014 | Current |
Financial Performance of Litsa Pharmaceuticals.
Litsa Pharmaceuticals Private Limited, for the financial year ended 2016, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 183.58% increase in profit. The company's net worth moved up by a moderate rise of 5.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Litsa Pharmaceuticals?
In 2017, Litsa Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Litsa Pharmaceuticals?
Unlock and access historical data on people associated with Litsa Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Litsa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Litsa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
